🇯🇵 Japan Country × Condition
biliary tract cancer Clinical Trials in Japan
Active clinical trials for biliary tract cancer with research sites in Japan. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 1, Phase 2 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇯🇵 Japan
Active Trials in Japan (2)
NCT06943521 Phase 1, Phase 2
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Enrollment
27 pts
Country
🇯🇵 Japan
Tanabe Pharma America, Inc.
View Trial → NCT06793709
Recruiting
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Enrollment
60 pts
Country
🇯🇵 Japan
Eisai Co., Ltd.
View Trial → Frequently Asked Questions
How many biliary tract cancer clinical trials are active in Japan?
There are currently 2 active clinical trials for biliary tract cancer with sites in Japan, of which 2 are actively recruiting patients.
How can I join a biliary tract cancer clinical trial in Japan?
To join a biliary tract cancer clinical trial in Japan, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Japan directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are biliary tract cancer trials in Japan?
Active biliary tract cancer trials in Japan span Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology